Immunoprecise Antibodies Ltd expected to post a loss of 9 cents a share - Earnings Preview

Reuters12-06

<a href="https://laohu8.com/S/IPA">Immunoprecise Antibodies Ltd</a> <ipa.oq> expected to post a loss of 9 cents a share - Earnings Preview </ipa.oq>

Immunoprecise Antibodies Ltd IPA.OQ IPA.O is expected to show a rise in quarterly revenue when it reports results on December 10 for the period ending October 31 2024
The Victoria British Columbia-based company is expected to report a 4.7% increase in revenue to C$6.439 million from C$6.15 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Immunoprecise Antibodies Ltd is for a loss of 9 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Immunoprecise Antibodies Ltd is $6.00, above its last closing price of $0.37.

This summary was machine generated December 6 at 13:34 GMT. All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489280039?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-06 21:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489280039","market":"us","top_or_hot":-1,"title":"Immunoprecise Antibodies Ltd  expected to post a loss of 9 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/IPA\">Immunoprecise Antibodies Ltd</a> <ipa.oq> expected to post a loss of 9 cents a share - Earnings Preview </ipa.oq></title></head><body><ul><li><p>Immunoprecise Antibodies Ltd <span>IPA.OQ</span> <span>IPA.O</span> is expected to show a rise in quarterly revenue when it reports  results on December 10 for the period ending October 31 2024</p></li><li><p>The <a href=\"https://laohu8.com/S/VCCTF\">Victoria</a> British Columbia-based  company is expected to report a 4.7% increase in revenue to C$6.439 million from C$6.15 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.</p></li><li><p>LSEG's mean analyst estimate for Immunoprecise Antibodies Ltd is for a loss of 9 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Immunoprecise Antibodies Ltd is $6.00, above its last closing price of $0.37. </p></li></ul><p>This summary was machine generated December 6 at 13:34 GMT.  All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immunoprecise Antibodies Ltd  expected to post a loss of 9 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunoprecise Antibodies Ltd  expected to post a loss of 9 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-06 21:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nL5N3N70VX:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Immunoprecise Antibodies Ltd  expected to post a loss of 9 cents a share - Earnings Preview Immunoprecise Antibodies Ltd IPA.OQ IPA.O is expected to show a rise in quarterly revenue when it reports  ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nL5N3N70VX:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPA","symbol_name":"Immunoprecise Antibodies Ltd","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nL5N3N70VX:1","article_id":"2489280039","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489280039","pubTimestamp":1733492059,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Immunoprecise Antibodies Ltd  expected to post a loss of9cents a share - Earnings Preview Immunoprecise Antibodies Ltd IPA.OQ IPA.O is expected to show a rise in quarterly revenue when it reports  res","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"IPA":"Immunoprecise Antibodies Ltd"},"translate_title":"Immunoprecise Antibodies Ltd预计每股亏损9美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPA":0.9},"content_text":"Immunoprecise Antibodies Ltd  expected to post a loss of 9 cents a share - Earnings Preview Immunoprecise Antibodies Ltd IPA.OQ IPA.O is expected to show a rise in quarterly revenue when it reports  results on December 10 for the period ending October 31 2024The Victoria British Columbia-based  company is expected to report a 4.7% increase in revenue to C$6.439 million from C$6.15 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.LSEG's mean analyst estimate for Immunoprecise Antibodies Ltd is for a loss of 9 cents per share. The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Immunoprecise Antibodies Ltd is $6.00, above its last closing price of $0.37. This summary was machine generated December 6 at 13:34 GMT.  All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489280039"}